HC Wainwright Brokers Reduce Earnings Estimates for LEXX

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Lexaria Bioscience in a report issued on Monday, December 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.12) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Lexaria Bioscience’s Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.46) EPS.

Lexaria Bioscience Price Performance

Shares of NASDAQ:LEXX opened at $2.70 on Wednesday. Lexaria Bioscience has a 12 month low of $1.20 and a 12 month high of $6.85. The stock has a market cap of $47.12 million, a price-to-earnings ratio of -5.74 and a beta of 0.99. The stock’s 50 day moving average price is $2.58 and its 200 day moving average price is $2.97.

Hedge Funds Weigh In On Lexaria Bioscience

Several institutional investors and hedge funds have recently modified their holdings of LEXX. Renaissance Technologies LLC purchased a new position in shares of Lexaria Bioscience during the 2nd quarter valued at $63,000. Armistice Capital LLC acquired a new position in Lexaria Bioscience during the 2nd quarter worth $2,836,000. HighTower Advisors LLC acquired a new position in shares of Lexaria Bioscience during the third quarter valued at about $40,000. XTX Topco Ltd raised its position in shares of Lexaria Bioscience by 47.8% during the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after buying an additional 6,024 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Lexaria Bioscience by 31.0% during the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after buying an additional 35,608 shares during the last quarter. 13.06% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Richard Christopher acquired 22,828 shares of the stock in a transaction on Monday, December 2nd. The shares were purchased at an average cost of $2.24 per share, for a total transaction of $51,134.72. Following the transaction, the chief executive officer now owns 22,828 shares in the company, valued at approximately $51,134.72. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 26.40% of the stock is currently owned by company insiders.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.